SCHEMBL20140527

SCHEMBL20140527

COc1ccc(C(CC(=O)O)N2C[C@H](CCCCC(C)=O)C2=O)cn1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 16/20 0.45
ITGB3 P05106 15/20 0.45
ITGB1 P05556 3/20 0.44
ITGA5 P08648 2/20 0.44
ITGA2B P08514 2/20 0.44
ITGB6 P18564 2/20 0.44
ITGB8 P26012 2/20 0.44
ITGA4 P13612 1/20 0.36
ITGB5 P18084 1/20 0.36
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
CHRNA7 P36544 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21314451 1.00 ITGAV (0.45) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL20158363 0.89 ITGB3 (0.37) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL30487533 0.89 ITGB3 (0.37) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL21314501 0.87 ITGAV (0.42) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL20140718 0.87 ITGAV (0.42) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL20142245 0.83 ITGAV (0.48) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL20158279 0.79 ITGAV (0.71) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL20141183 0.79 ITGAV (0.71) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL29701391 0.79 ITGAV (0.71) ITGAVITGB3ITGB1ITGA5ITGA2B
SCHEMBL21314474 0.79 ITGAV (0.46) ITGAVITGB3ITGB1ITGA5ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3538526-A1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS Bristol-Myers Squibb Company (US) 2019-09-18 EP disclosed
WO-2018089355-A1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-17 WO disclosed